These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2231320)

  • 1. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic and beta-blocker therapy.
    Myers MG; Leenen FH; Burns R; Frankel D
    Clin Pharmacol Ther; 1986 Apr; 39(4):409-13. PubMed ID: 2869849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy.
    Hansson L; Dahlöf B; Gudbrandsson T; Hellsing T; Kullman S; Kuylenstierna J; Leppert J; Möller B; Skogström K; Svensson A
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):94-101. PubMed ID: 2459541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
    Adir J; Janda SM; Curry CL; Taylor RE; Poku CD; Rotenberg KS
    Clin Ther; 1987; 9(6):640-50. PubMed ID: 3326679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
    Chazan BI; Duff DA; McCallum A; Whaley K
    Curr Med Res Opin; 1986; 10(3):150-8. PubMed ID: 2873966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.
    Br J Clin Pharmacol; 1986 Jun; 21(6):621-6. PubMed ID: 2874821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
    Rowell NP; Clark K
    Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial.
    Circulation; 1981 Oct; 64(4):772-9. PubMed ID: 7023744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients.
    Jackson SH; Shepherd AM; Ludden TM; Jamieson MJ; Woodworth J; Rogers D; Ludden LK; Muir KT
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):624-8. PubMed ID: 1706804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.